Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 语言: | 英语 |
| 出版: |
2016
|
| 在线阅读: | https://doi.org/10.1158/2326-6066.cir-15-0193 https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|